Abacavir

阿巴卡韦是一种具有口服活性和竞争性的核苷类逆转录酶抑制剂。

此产品仅用于科学研究，我们不为任何个人用途提供产品和服务

库存: 现货

可选规格

包装

价格

促销价

数量
10mg

￥437.00

350.00

- +
50mg

￥862.00

690.00

- +

已选 0 种 0 瓶

金额: ￥0.00

首页收藏

货号: ajci11852
CAS: 136470-78-5
别名: 阿巴卡韦
分子式: C14H18N6O
分子量: 286.33
纯度: >98%
溶解度: ≥ 30.7 mg/mL in DMSO with gentle warming, ≥ 39.3 mg/mL in EtOH with gentle warming, ≥ 7.16 mg/mL in Water
储存: Store at -20°C
库存: 现货

Background

IC50 Value: 0.26 microM for HIV-1[1] Abacavir,(-)-(1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol, is a novel purine carbocyclic nucleoside analogue that has been approved by the FDA for the treatment of HIV (as Ziagen trade mark [abacavir sulfate]) [2]. in vitro: In erythrocytes, abacavir influx was rapid, nonsaturable (rate constant=200 pmol/s/mM/microl cell water), and unaffected by inhibitors of nucleoside or nucleobase transport[2]. in vivo: pharmacokinetic, distribution, and toxicological profiles of 1592U89 were distinct from and improved over those of CBV, probably because CBV itself was not appreciably formed from 1592U89 in cells or animals (<2%). The 5'-triphosphate of CBV was a potent, selective inhibitor of HIV-1 RT, with Ki values for DNA polymerases (alpha, beta, gamma, and epsilon which were 90-, 2,900-, 1,200-, and 1,900-fold greater, respectively, than for RT (Ki, 21 nM). 1592U89 was relatively nontoxic to human bone marrow progenitors erythroid burst-forming unit and granulocyte-macrophage CFU (IC50s, 110 microM) and human leukemic and liver tumor cell lines[1]. Clinical trial: Estimate The Effect Of Lersivirine On The Pharmacokinetics Of Abacavir + Lamivudine In Healthy Subjects. Phage1